Anticonvulsant drugs for status epilepticus to hospital discharge*
| Outcomes | Number of trials (n) | Comparisons | Event rates | RRR (95% CI) | NNT (CI) |
|---|---|---|---|---|---|
| *Abbreviations defined in glossary; weighted event rates, RRR, NNT, and CI calculated from data in article using a fixed effects model. All drugs given intravenously unless otherwise noted. Event rates with 1 trial are unweighted. | |||||
| Non-cessation of seizures | 3 (264) | Lorazepam v diazepam | 24% v 38% | 36% (10 to 55) | 8 (5 to 25) |
| 1 (137) | Lorazepam v placebo | 41% v 79% | 48% (29 to 62) | 3 (2 to 5) | |
| 1 (198) | Lorazepam v phenytoin | 35% v 56% | 38% (14 to 55) | 5 (3 to 13) | |
| 1 (139) | Diazepam v placebo | 57% v 79% | 27% (8 to 43) | 5 (3 to 17) | |
| 2 (165) | Intrarectal diazepam gel v placebo | 32% v 72% | 57% (38 to 70) | 3 (2 to 4) | |
| 1 (39) | Intrarectal diazepam gel 30 mg v 20 mg | 28% v 71% | 61% (14 to 82) | 3 (2 to 7) | |
| Continuation of status epilepticus requiring a different drug | 3 (264) | Lorazepam v diazepam | 24% v 39% | 37% (12 to 55) | 7 (4 to 25) |
| 1 (137) | Lorazepam v placebo | 41% v 79% | 48% (29 to 62) | 3 (2 to 5) | |
| 1 (139) | Diazepam v placebo | 57% v 79% | 27% (8 to 43) | 5 (3 to 17) | |
| Death | 1 (139) | Diazepam v placebo | 4.4% v 15% | 72% (2 to 92) | 10 (5 to 100) |
| Ventilatory support | 1 (139) | Diazepam v placebo | 8.8% v 23% | 61% (6 to 84) | 8 (4 to 50) |